Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results (NYSE:RCUS)

Young Female Scientist Noting Results Of Experiment In A Lab

AzmanJaka/E+ via Getty Images

Arcus Biosciences (NYSE:RCUS) is a biopharmaceutical company specializing in cancer therapeutics that are operating at the clinical stage. Their lead candidate, domvanalimab, has displayed potential through trials for metastatic non-small cell lung cancer (NSCLC).

Despite

Revenue and R&D Expenses

ycharts.com

PIpeline

investors.arcusbio.com/investors-and-media/events-and-presentations/corporate-presentation/default.aspx

Calendar of Milestones

investors.arcusbio.com/investors-and-media/events-and-presentations/corporate-presentation/default.aspx

Study Methodology

investors.arcusbio.com/investors-and-media/events-and-presentations/corporate-presentation/default.aspx

Be the first to comment

Leave a Reply

Your email address will not be published.


*